Srilatha Edupuganti MD
Overview
Dr. Edupuganti received her MD degree from Louisiana State University School of Medicine in New Orleans. She completed her residency in Internal Medicine at Parkland Memorial Hospital University of Texas Southwestern Medical Center, and her Infectious Diseases Fellowship at Emory University and the University of North Carolina, Chapel Hill School of Medicine. She also received a MPH in Epidemiology form the University of North Carolina School of Public Health. In September 2006, she joined the faculty of the Division of Infectious Diseases as a member of the Hope Clinic where vaccine clinical trials are conducted.
Dr. Edupugantis research interests are translational research in vaccines and vaccine development. She is based at the Hope Clinic of Emory Vaccine Center and serves as the Medical Director. She has been focused on HIV vaccine development for the past 10 years. She is the Hope Clinic CRS leader for the DAIDS funded Emory-CDC Clinical Trials Unit. She is a site investigator/co-investigator for the HIV Vaccine Trials Network (HVTN) studies that are being conducted at the Hope clinic. She serves as the Clinical Core leader for translational immunology projects funded by CCHI of NIAID.
She is an attending physician at Emory Healthcare.
She is involved in the teaching, administrative activities and conferences of the Division of Infectious Diseases including lectures, interviews, journal club, case of the week and research seminars. At the Hope Clinic, she participates in the training of junior, international, and minority investigators in vaccine clinical trials, methodologies, provides education, prevention, and community outreach services, which includes speaking to community and other groups regarding vaccine development.
Academic Appointment
- Professor of Medicine, Emory Univesity School of Medicine
Education
Degrees
- MPH from UNC-School of Public Health
- MD from Louisiana State University School of Medicine
- BS from Loyola University
Research
Focus
- My primary research interest is in translational studies of vaccines and vaccine clinical trials. I have been involved either as a site principal investigator or co-investigator and conducted clinical trials of HIV vaccines, influenza vaccines including H1N1 and avian influenza vaccines, yellow fever vaccine, smallpox vaccine and others. I served as the site principal investigator for several Merck phase I HIV vaccine clinical trials that included DNA vaccines with or without adjuvants, adenovirus vaccines, and canarypox vector based vaccines.
Publications
-
Fixed dosing versus weight-based dosing of HIV-1 prophylactic monoclonal antibodies in adults: a post-hoc, cross-protocol pharmacokinetics modelling study.
EBioMedicine Volume: 117 Page(s): 105804
07/01/2025 Authors: Huang Y; Zhang L; Gelderblom H; Seaton KE; Yates NL; Paez CA; Karuna ST; Andrew P; Gamble T; Robinson ST -
Vaccination with mRNA-encoded nanoparticles drives early maturation of HIV bnAb precursors in humans.
Science Page(s): eadr8382
05/15/2025 Authors: Willis JR; Prabhakaran M; Muthui M; Naidoo A; Sincomb T; Wu W; Cottrell CA; Landais E; deCamp AC; Keshavarzi NR -
Mucosal and Systemic Antibody Responses After Boosting With a Bivalent Messenger RNA Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine.
J Infect Dis
04/29/2025 Authors: Atmar RL; Lyke KE; Posavad CM; Deming ME; Brady RC; Dobrzynski D; Edupuganti S; Mulligan MJ; Rupp RE; Rostad CA -
Brief Report: Associations Between Gender and Solicited Adverse Events After Passive Infusion of VRC01 or Placebo in HVTN 704/HPTN 085.
J Acquir Immune Defic Syndr Volume: 98 Page(s): 340 - 345
04/01/2025 Authors: Theodore DA; Neradilek M; Gillespie K; Edupuganti S; Hinojosa JC; Lama JR; De La Grecca R; Wu YH; Davis A; Mangini D -
Pharmacokinetic interaction assessment of an HIV broadly neutralizing monoclonal antibody VRC07-523LS: a cross-protocol analysis of three phase 1 trials in people without HIV.
BMC Immunol Volume: 26 Page(s): 8
02/19/2025 Authors: Chawana TD; Walsh SR; Stranix-Chibanda L; Chirenje ZM; Yu C; Zhang L; Seaton KE; Heptinstall J; Zhang L; Paez CA -
Rare twin cysteine residues in the HIV-1 envelope variable region 1 link to neutralization escape and breadth development.
Cell Host Microbe Volume: 33 Page(s): 279 - 293.e6
02/12/2025 Authors: Hesselman MC; Zeeb M; Rusert P; Pasin C; Mamrosh J; Kariuki S; Pichler I; Sickmann M; Kaufmann MM; Schmidt D -
Neutralizing Antibody Immune Correlates for a Recombinant Protein Vaccine in the COVAIL Trial.
Clin Infect Dis Volume: 80 Page(s): 223 - 227
02/05/2025 Authors: Fong Y; Dang L; Zhang B; Fintzi J; Chen S; Wang J; Rouphael NG; Branche AR; Diemert DJ; Falsey AR -
Retrospective analysis of sex-disaggregated immune responses to ALVAC-HIV and bivalent subtype C gp120/MF59 HIV vaccines.
Front Immunol Volume: 16 Page(s): 1557009
01/01/2025 Authors: Ackerley CG; Edupuganti S; Yu C; Roxby AC; Seaton KE; Bekker L-G; Allen M; DeRosa SC; Yates NL; Heptinstall J -
Safety, tolerability, pharmacokinetics, and neutralisation activities of the anti-HIV-1 monoclonal antibody PGT121.414.LS administered alone and in combination with VRC07-523LS in adults without HIV in the USA (HVTN 136/HPTN 092): a first-in-human, open-label, randomised controlled phase 1 trial.
Lancet HIV Volume: 12 Page(s): e13 - e25
01/01/2025 Authors: Edupuganti S; Hurt CB; Stephenson KE; Huang Y; Paez CA; Yu C; Yen C; Hanscom B; He Z; Miner MD -
Use of 3M-052-AF with Alum adjuvant in HIV trimer vaccine induces human autologous neutralizing antibodies.
J Exp Med Volume: 221
10/07/2024 Authors: Hahn WO; Parks KR; Shen M; Ozorowski G; Janes H; Ballweber-Fleming L; Woodward Davis AS; Duplessis C; Tomai M; Dey AK